Uev1A counteracts oncogenic *Ras* stimuli in both polyploid and diploid cells

Qi Zhang[1†], Yunfeng Wang[1†], Xueli Fu[2†], Ziguang Wang[1†], Yang Zhang[1], Lizhong Yan[1],

Yuejia Wang[1], Muhan Yang[1], Dongze Song[1], Ruixing Zhang[2], Hongru Zhang[2,3*], Shian

Wu[1*], and Shaowei Zhao[1*]

[1]Department of Genetics and Cell Biology,

[2]Department of Biochemistry and Molecular Biology,

College of Life Sciences, Nankai University, Tianjin, 300071, People's Republic of China

[3]Nankai International Advanced Research Institute (SHENZHEN FUTIAN), Shenzhen 518045, People's Republic of China

[†]These authors contributed equally

*For correspondence: hrzhang@nankai.edu.cn; wusa@nankai.edu.cn; swzhao@nankai.edu.cn

Abstract

Oncogenic *Ras* is known to induce DNA replication stress, leading to cellular senescence or death. In contrast, we found that it can also trigger polyploid *Drosophila* ovarian nurse cells to die by inducing aberrant division stress. To explore intrinsic protective mechanisms against this specific form of cellular stress, here we conducted a genome-wide genetic screen and identified the E2 enzyme Uev1A as a key protector. Reducing its expression levels exacerbates the nurse cell death induced by oncogenic *Ras*, while overexpressing it or its human homologs, UBE2V1 and UBE2V2, mitigates this effect. Although Uev1A is primarily known for its non-proteolytic functions, our studies demonstrate that it collaborates with the E3 APC/C complex to mediate the proteasomal degradation of Cyclin A, a key cyclin that drives cell division. Furthermore, Uev1A and UBE2V1/2 also counteract oncogenic *Ras*-driven tumorigenesis in diploid cells, suppressing the overgrowth of germline tumors in *Drosophila* and human colorectal tumor xenografts in nude mice, respectively. Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic *KRAS* mutations, indicating that their upregulation could represent a promising therapeutic strategy.

Introduction

Although the human body contains trillions of cells that could potentially be targeted by oncogenic mutations, cancers arise infrequently throughout a human lifetime, suggesting the presence of effective resistance mechanisms (**Lowe et al., 2004**). One key mechanism involves the induction of DNA replication stress by these oncogenic mutations, leading to cellular senescence or death (**Hills and Diffley, 2014; Kotsantis et al., 2018**). This mechanism is mediated through the activation of the DNA damage response (DDR) pathway and the tumor suppressor protein p53, which are triggered by DNA double-strand breaks (DSBs). Only the cells that escape senescence and death, such as those harboring *p53* mutations, can undergo transformation by oncogenic mutations, thereby initiating tumorigenesis (**Gaillard et al., 2015; Igarashi et al., 2024; Macheret and Halazonetis, 2015**). Among the most frequently mutated oncogenes in human cancers are the *RAS* genes (*KRAS*, *NRAS*, and *HRAS*), which mutations are present in 20-30% of all cancer cases (**Gimple and Wang, 2019; Sanchez-Vega et al., 2018**). These mutations often occur at codons 12, 13, and 61, resulting in RAS small GTPases being locked in a constitutively active, GTP-bound state (**Moore et al., 2020**). Notably, previous studies have shown that oncogenic $HRAS^{G12V}$ can induce DNA replication stress via the DDR pathway, ultimately leading to cellular senescence (**Di Micco et al., 2006; Serrano et al., 1997**).

The *Ras oncogene at 85D* gene (*Ras85D*, hereafter referred to as *Ras*) in *Drosophila* exhibits high homology to human *RAS* genes (**Neuman-Silberberg et al., 1984**). Our previous research demonstrated that oncogenic Ras^{G12V} triggers cell death in *Drosophila* ovarian nurse cells (**Zhang et al., 2024**), a type of post-mitotic germ cells that undergo G/S endoreplication to become polyploid (**Hammond and Laird, 1985**) (**Figure 1A**). Notably, oncogenic Ras^{G12V} promotes the division of mitotic germ cells, the

precursors to nurse cells. Furthermore, monoallelic deletion of the *cyclin A* (*cycA*) or

cyclin-dependent kinase 1 (*cdk1*) gene (*cycA$^{+/-}$* or *cdk1$^{+/-}$*) suppresses *Ras^{G12V}*-induced

nurse cell death (**Zhang et al., 2024**). While CycA, a key cyclin promoting cell division, is

not expressed in normal nurse cells (**Lilly et al., 2000; Lilly and Spradling, 1996**), its

ectopic expression in nurse cells can trigger their death (as observed in this study).

These findings suggest that the nurse cell death induced by oncogenic *Ras^{G12V}* is

primarily due to aberrant promotion of cell division. *Drosophila* ovarian nurse cells thus

offer a valuable model for studying this specific form of cellular stress.

Ubiquitination not only mediates protein degradation through the proteasome or

lysosome but also plays crucial regulatory roles in various biological processes (**Dikic,**

2017; Kwon and Ciechanover, 2017). These functions are largely determined by the

topological structures of the polyubiquitin chains, where ubiquitin can be linked to

another ubiquitin via any of its seven lysine (K) residues or its first methionine residue.

Among these, K11- and K48-linked polyubiquitin primarily mediates the proteasomal

degradation. In contrast, K63 linkage facilitates the lysosomal degradation of protein

aggregates and damaged organelles through autophagy. Additionally, K63 linkage is

involved in non-degradative processes such as DNA repair, kinase activation, and

protein transport (**Kwon and Ciechanover, 2017**). Ubc13 is a ubiquitin-conjugating (E2)

enzyme that specifically catalyzes the formation of the K63 linkage. However, this

activity requires a unique cofactor known as Ubc variant (Uev). Uev proteins lack the

catalytic cysteine residue necessary for ubiquitin thioester formation; instead, they work

with Ubc13 to form a functional E2 complex (**Hofmann and Pickart, 1999; McKenna et**

al., 2001). These E2 enzymes have been shown to play regulatory roles in various

biological processes, including cell death (**Ma et al., 2013**), DNA repair (**Broomfield et**

al., 1998), DDR, and innate immunity (**Andersen et al., 2005; Bai et al., 2020; Zhou et**

al., 2005). However, it still remains unknown whether they also possess proteasomal

proteolytic functions and whether such functions hold significant biological roles.

In this study, to investigate the intrinsic protective mechanisms against Ras^{G12V}-

induced nurse cell death in *Drosophila*, we conducted a genome-wide genetic screen

and identified Uev1A as a crucial protector. Mechanistically, Uev1A works in conjunction

with the anaphase-promoting complex or cyclosome (APC/C) to degrade the essential

cyclin CycA via the proteasome, highlighting the critical role of its proteolytic function.

Additionally, Uev1A and its human homologs, UBE2V1 and UBE2V2, also counteract

oncogenic *Ras*-driven tumorigenesis in diploid cells, inhibiting the overgrowth of

Drosophila germline tumors and human colorectal tumor xenografts in nude mice,

respectively. These findings suggest that upregulation of UBE2V1/2 could represent a

promising therapeutic approach for human colorectal cancers with *RAS* mutations.

Results

Genetic screen identifies Uev1A as a crucial protector against *Ras^(G12V)*-induced nurse cell death

While oncogenic *Ras^(G12V)* triggers cell death in nurse cells, it does not have the same effect in cystocytes, the precursor cells before differentiating into nurse cells (***Zhang et al., 2024***). To confirm Ras^(G12V) expression in cystocytes, we generated a *UASz-flag-Ras^(G12V)* transgenic fly strain, which phenocopied the effects observed with the previously used *UASp-Ras^(G12V)*. RAS small GTPases need to be anchored to the inner cell membrane for their proper function (***Willingham et al., 1980***). Using *bam-GAL4-VP16* (***Chen and McKearin, 2003***), we overexpressed Ras^(G12V) specifically in cystocytes (*bam>flag-Ras^(G12V)*) at 29°C and observed membrane-localized Flag signals, validating the normal expression of Ras^(G12V) (***Figure 1B***). Also, Flag signals were detected in some early-stage nurse cells, although these signals gradually diminished over time (***Figure 1B***). During cell death, nurse cell nuclei progress through distinct morphological stages: from large and round, to disorganized and condensed, and finally to completely fragmented into small, spherical structures (***Figure 1D***). Given the interconnection and synchronous death of all nurse cells within an egg chamber, we quantified this death phenotype at the egg-chamber level. Notably, nurse cell death remained very low in *bam>flag-Ras^(G12V)* fly ovaries (***Figure 1D, E***). This may be attributed to either insufficient levels of the oncoproteins or the presence of a protective mechanism.

To explore the potential protective mechanism, we conducted a genetic modifier screen by introducing individual genome-wide *Deficiencies* (361 lines) into *bam>Ras^(G12V)* flies (***bam>Ras^(G12V); Deficiency/+, Figure 1C***). Of note, ovaries from *bam>Ras^(G12V); Df#7584/+* flies exhibited the highest incidence of degrading egg chambers with dying

nurse cells per ovary (**see Source data 1**). One gene deleted in this deficiency line is

uev1a, and RNAi targeting *uev1a* reproduced the phenotype seen with *Df#7584* (**Figure**

1D, E). In this and all subsequent experiments, we quantified the nurse-cell-death

phenotype using the percentage of degrading to total egg chambers per ovary (**Figure**

1E), a method that is more precise than our approach in the genetic screen. To further

verify the role of *uev1a*, we generated a *UASz-uev1a* transgenic fly strain.

Overexpression of Uev1A successfully rescued the nurse-cell-death phenotype in

bam>Ras^{G12V}; Df#7584/+ fly ovaries (**Figure 1D, E**), confirming that Uev1A is a crucial

protector against *Ras^{G12V}*-induced nurse cell death.

Protective role of Uev1A against the nurse cell death induced by direct
overexpression of Ras^{G12V}

In contrast to the scenario above (*bam>Ras^{G12V}*), direct overexpression of Ras^{G12V} in

nurse cells using *nos-GAL4-VP16* (Rørth, 1998; Van Doren et al., 1998) (*nos>Ras^{G12V}*)

resulted in substantial cell death even at 25°C (**Figure 2A, D**) (**Zhang et al., 2024**). Such

observation prompted us to investigate the role of Uev1A in this context. Notably, the

incidence of dying nurse cells was markedly elevated in *nos>Ras^{G12V}+uev1a-RNAi*

ovaries compared to the *nos>Ras^{G12V}+GFP-RNAi* control ovaries (**Figure 2A, D**). To

further validate this, we generated two *uev1a* mutants using the CRISPR/Cas9

technique: *uev1a^{Δ1}* and *uev1a^{Δ2}*. Both mutations consist of small deletions that cause

frame shifts within the second coding exon of the *uev1a* gene (**Figure 2B**). Of note, flies

with the *uev1a$^{Δ1/Δ1}$*, *uev1a$^{Δ1/Δ2}$*, *uev1a^{Δ1}/Df#7584*, *uev1a$^{Δ2/Δ2}$*, or *uev1a^{Δ2}/Df#7584*

genotype could not survive into adults, suggesting that both mutations are strong loss-of-

function alleles. Consistent with the effects observed with *uev1a-RNAi*, either mutation

markedly increased the incidence of dying nurse cells in *nos>Ras^{G12V}* ovaries (**Figure**

2C, D).

We next investigated whether upregulating Uev1A could mitigate the nurse cell

death induced by direct overexpression of Ras^{G12V}. Remarkably, compared to the

$nos>Ras^{G12V}+lacZ$ control ovaries, the incidence of dying nurse cells was significantly

reduced in $nos>Ras^{G12V}+Uev1A$ ovaries (**Figure 2F, G**). Uev1A has two human

homologs, UBE2V1 and UBE2V2, which share 67% (85%) and 67% (86%) sequence

identities (similarities) with Uev1A, respectively (**Figure 2E**). We generated transgenic fly

strains for both *UASz-UBE2V1* and *UASz-UBE2V2*. Notably, overexpression of either

UBE2V1 or UBE2V2 significantly mitigated Ras^{G12V}-induced nurse cell death, similar to

the effects observed with Uev1A overexpression (**Figure 2F, G**). Taken together, these

results further confirm the protective role of Uev1A against Ras^{G12V}-induced nurse cell

death.

Then, we were intrigued by the potential of Uev1A to protect against the nurse

cell death induced by other oncogenic mutations. Yorkie (Yki), a key oncoprotein in the

Hippo pathway (**Huang et al., 2005**), has a hyperactive form known as Yki^{3SA} (**Oh and**

Irvine, 2009). Its overexpression using *nos-GAL4-VP16* ($nos>Yki^{3SA}$) at 29°C, but not at

25°C, could induce nurse cell death (**Figure 2—figure supplement 1**), albeit much less

severe than that induced by $nos>Ras^{G12V}$ at 25°C (compared with **Figure 2A, D**). Of note,

the nurse cell death induced by oncogenic Yki^{3SA} was significantly alleviated by Uev1A

overexpression (**Figure 2—figure supplement 1**), implying a broad role of Uev1A in this

process. However, due to the mild effect of Yki^{3SA} on triggering nurse cell death, we

focused on Ras^{G12V} in our subsequent studies.

The DDR pathway and p53 play opposite roles in Ras^{G12V}-induced nurse cell death

To investigate how Uev1A protects against Ras^{G12V}-induced nurse cell death, we first

sought to further explore the mechanisms driving this cell death. Since egg chambers

contain both nurse cells and oocytes (*Figure 1A*), we considered the possibility that the

death signal could originate from oocytes. The *Bicaudal D* (*BicD*) gene is essential for

oocyte determination, and egg chambers deficient in it fail to specify oocytes (**Suter and**

Steward, 1991). We confirmed this by using *nos>BicD-RNAi* (**Figure 3—figure**

supplement 1A). Importantly, nurse cell death was much more pronounced in

nos>BicD-RNAi+Ras^{G12V} egg chambers than in *nos>BicD-RNAi+GFP* control ones

(**Figure 3—figure supplement 1A, B**), indicating that the death signal is intrinsic to

nurse cells rather than originating from oocytes.

Oncogenic *RAS* can induce DNA replication stress in diploid cells, thereby

activating the DDR pathway and p53 to trigger cellular senescence or death (**Di Micco**

et al., 2006; Serrano et al., 1997). To investigate whether DDR plays a similar role in

Ras^{G12V}-induced nurse cell death, we targeted two key DDR genes: *telomere fusion* (*tefu*,

encoding *Drosophila* ATM) (**Oikemus et al., 2004; Silva et al., 2004; Song et al., 2004**)

and *loki* (*lok*, encoding *Drosophila* Chk2) (**Masrouha et al., 2003; Xu et al., 2001**).

Strikingly, knockdown of either gene markedly enhanced this cell death (**Figure 3A, B**),

revealing a protective role for the DDR pathway. By contrast, knockdown of *p53*

suppressed this cell death (**Figure 3A, B**), demonstrating opposing functions for DDR

and p53 in this context. To assess DNA DSBs and the ensuing DDR, we monitored the

phosphorylation of γH2AV, the *Drosophila* histone variant analogous to mammalian

H2AX (**Lake et al., 2013**). As egg chamber developmental stages are difficult to discern

during degradation, we compared size-matched egg chambers, which are typically

stage-matched under normal conditions and have comparable antibody penetration.

Elevated γH2AV staining was observed in degrading *nos>Ras^{G12V}* egg chambers

compared to *nos>GFP* controls (**Figure 3C**), indicating a heightened burden of DNA

DSBs.

Given that RNAi targeting *tefu* or *lok* phenocopied that of *uev1a*, we

hypothesized that Uev1A protects against Ras^{G12V}-induced nurse cell death through the

DDR pathway. If so, Uev1A may also be upregulated in response to Ras^{G12V}-driven

stress. To test this, we initially attempted to generate an antibody against Uev1A using

its full protein sequence as the antigen; however, this approach was unsuccessful. As an

alternative, we created a *uev1a-flag* knock-in fly strain by inserting the coding sequence

of a 3xFlag tag immediately before the stop codon ("TAG") of the *uev1a* gene (**Figure**

3D). These knock-in flies were homozygous viable and fertile, indicating that the Flag

insertion did not disrupt Uev1A's normal function. Previous studies have shown that

Uev1A can activate JNK signaling (**Ma et al., 2013**), which acts in the surrounding follicle

cells to promote nurse cell removal during late oogenesis **(Timmons et al., 2016**).

Indeed, we detected Uev1A-Flag signals in such follicle cells (**Figure 3—figure**

supplement 2), confirming that these signals reflect endogenous Uev1a expression in

Drosophila ovaries. Surprisingly, Uev1A-Flag signals were low in both *nos>Ras^{G12V};*

uev1a-flag/+ and *uev1a-flag/+* control nurse cells, with no significant differences

between the two groups (**Figure 3E**). This suggests that Uev1A expression remains at

basal levels, rather than being upregulated by Ras^{G12V}-driven stress in this context.

Although we cannot rule out the possibility that Uev1A may play a role in the DDR

pathway at these basal levels, these findings prompted us to explore its potential

proteolytic function as an E2 enzyme.

Following the Occam's Razor principle, we first investigated whether Uev1A is

involved in downregulating Ras^{G12V} oncoprotein levels. To address the challenges of

analyzing membrane-localized signals in *nos>flag-Ras^{G12V}* nurse cells due to severe cell

death, we performed this assay in *bam>flag-Ras^{G12V}* ovaries at 29°C. Notably, similar

membrane-localized Flag signals were detected in both *bam>flag-Ras^{G12V}+Uev1A* and

bam>flag-Ras^{G12V}+GFP control germ cells, including nurse cells (**Figure 3—figure**

supplement 3). This result suggests that Uev1A does not downregulate Ras^{G12V}

oncoprotein levels.

218 Uev1A downregulates CycA protein levels in *Ras^{G12V}*-induced dying nurse cells

Our previous research demonstrated that oncogenic *Ras^{G12V}* promotes germline stem

cell (GSC) over-proliferation by activating the mitogen-activated protein kinase (MAPK)

pathway (**Zhang et al., 2024**). This finding led us to investigate whether the same

pathway influences *Ras^{G12V}*-induced nurse cell death. Notably, knockdown of

downstream of raf1 (*dsor1*, encoding *Drosophila* MAPKK) (**Tsuda et al., 1993**) or *rolled*

(*rl*, encoding *Drosophila* MAPK) (**Biggs and Zipursky, 1992**) significantly mitigated

Ras^{G12V}-induced nurse cell death (**Figure 4A, B**), highlighting the pivotal role of the

MAPK pathway in this process.

The Ras/MAPK pathway is well known to promote cell cycle progression (**Gimple**

and Wang, 2019). Our previous work demonstrated that reducing the gene dosage of

CycA or *Cdk1* suppresses *Ras^{G12V}*-induced nurse cell death (**Zhang et al., 2024**). In

addition to CycA and Cdk1, Cyclin B (CycB) and String (Stg) are two other essential

regulators that drive cell division (**Figure 4C**) (**Edgar and Lehner, 1996**). To determine if

individual overexpression of these regulators could induce nurse cell death, we tested

each and found that only CycA triggered this phenotype (**Figure 4C, D**). Notably, this

cell death was suppressed by co-overexpression of CycA and Uev1A (**Figure 4C, D**),

indicating a genetic interaction between them. In line with previous findings (**Lilly et al.,**

2000; Lilly and Spradling, 1996), CycA protein was undetectable in wild-type

endocycling nurse cells (**Figure 4E**). In stark contrast, it was abundantly expressed in

dying *nos>Ras^{G12V}* nurse cells (**Figure 4E**), underscoring a critical role for CycA in this

cell death process. Additionally, we assessed CycA protein levels in size-matched

nos>Ras^G12V nurse cells under either *uev1a* or *GFP* (control) knockdown condition.

Notably, *uev1a* knockdown increased CycA levels compared with the controls (**Figure**

4F, G), demonstrating that Uev1A downregulates CycA protein levels in *Ras^G12V*-induced

dying nurse cells.

244   Uev1A collaborates with the APC/C complex to mitigate *Ras^G12V*-induced nurse cell

245   death

It is well-established that the APC/C complex primarily functions as an E3 ligase to

facilitate the degradation of CycA during cell cycle progression (**Sudakin et al., 1995**).

Thus, a compelling model to explain our findings is that Uev1A collaborates with the

APC/C complex to degrade CycA. Cell division cycle 27 (Cdc27, *Drosophila* APC3) is an

essential part of the substrate recognition TPR lobe within the APC/C complex (**Yamano,**

2019). In *bam>Ras^G12V+cdc27-RNAi* ovaries, we observed dying nurse cells, a

phenotype that was exacerbated with mutations in either *uev1a^Δ1* or *uev1a^Δ2* (**Figure 5A,**

B). Furthermore, knocking down *cdc27* could increase the incidence of dying nurse cells

in *bam>Ras^G12V+uev1a-RNAi* ovaries (**Figure 5A, B**). Also, we investigated Fizzy-related

(Fzr), the *Drosophila* homolog of Cdh1, that is a critical activator of APC/C-dependent

proteolysis. It is known that Fzr functions to downregulate mitotic cyclins, including CycA,

during cell entry into endocycles (**Sigrist and Lehner, 1997**). Remarkably, nearly all egg

chambers in *bam>Ras^G12V+uev1a-RNAi+fzr-RNAi* ovaries exhibited degradation (**Figure**

5A, B). Additionally, we knocked down three additional APC/C complex genes in

bam>Ras^G12V+uev1a-RNAi ovaries: *shattered* (*shtd*, encoding *Drosophila* APC1)

(**Tanaka-Matakatsu et al., 2007**), *morula* (*mr*, encoding *Drosophila* APC2) (**Kashevsky**

et al., 2002), and *lemming A* (*lmgA*, encoding *Drosophila* APC11) (**Nagy et al., 2012**).

Among these factors, Shtd is a critical component of the scaffolding platform, while Mr

and LmgA are essential components of the catalytic modules within the APC/C complex

(*Yamano, 2019*). However, no significant enhancement in nurse cell death was

observed, which may be due to the relatively mild phenotype of nurse cell death in

bam>Ras^{G12V}+uev1a-RNAi ovaries. Therefore, we switched to knocking down these

genes in *nos>Ras^{G12V}* ovaries. Notably, knockdown of any of them could significantly

exacerbated *Ras^{G12V}*-induced nurse cell death (*Figure 5C, D*), similar to the effect

observed with Uev1A downregulation. Collectively, these findings provide genetic

evidence that Uev1A collaborates with the APC/C complex to mitigate *Ras^{G12V}*-induced

nurse cell death.

Then, we investigated whether Uev1A and the APC/C complex protect nurse

cells from death during normal oogenesis. Given that the G2/M-promoting CycA is

absent in the G/S-endocycling nurse cells (*Figure 4E*) (*Lilly et al., 2000; Lilly and*

Spradling, 1996), we used the cystocyte-specific driver, *bam-GAL4-VP16*, to conduct

the assays at 29°C. Similar to nurse cells, Uev1A expression was at basal levels in

cystocytes, with some expression detected in inner sheath cells and epithelial follicle

cells (*Figure 5—figure supplement 1*). Remarkably, nearly all egg chambers in

bam>fzr-RNAi ovaries exhibited degradation (*Figure 5—figure supplement 2*),

underscoring Fzr's critical regulatory role in this context. Uev1A typically partners with

Bendless (Ben), the *Drosophila* homolog of mammalian Ubc13 (*Muralidhar and*

Thomas, 1993; Oh et al., 1994), to perform the E2 enzyme function (*Sancho et al.,*

1998; Zhou et al., 2005). Ovaries with the *bam>cdc27-RNAi*, *bam>cdc27-RNAi+uev1a-*

RNAi, or *bam>cdc27-RNAi+ben-RNAi* genotype showed minimal degradation of egg

chambers (*Figure 5—figure supplement 2*). However, degraded egg chambers were

prevalent in *bam>cdc27-RNAi+ben-RNAi; uev1a^{Δ1}/+* and *bam>cdc27-RNAi+ben-RNAi;*

uev1a^{Δ2}/+ ovaries, where Uev1A, Ben, and Cdc27 are all downregulated (*Figure 5—*

figure supplement 2). These results suggest that Uev1A, Ben, and the APC/C complex

also work together to protect nurse cells from death during normal oogenesis.

Uev1A and the APC/C complex work together to degrade CycA via the proteasome

The APC/C complex is known to collaborate with the E2 enzymes UBE2C (*Drosophila*

homolog: Vihar) and UBE2S (*Drosophila* homolog: Ube2S) to facilitate the proteasomal

degradation of CycA during cell cycle progression (**Greil et al., 2022; Yamano, 2019**).

This degradation involves the assembly of branched ubiquitin chains, incorporating K11,

K48, and K63 linkages through a two-step mechanism (**Meyer and Rape, 2014**).

However, the involvement of Uev1A in this process remains unexplored. To explore it,

we performed biochemical assays in cultured *Drosophila* Schneider 2 (S2) cells,

overexpressing tag-fused proteins using *act-GAL4* to enhance expression efficiency. Co-

immunoprecipitation (co-IP) assays revealed that Uev1A interacts with several

components of the APC/C complex, including Mr (*Drosophila* APC2), Cdc16 (*Drosophila*

APC6), and Cdc23 (*Drosophila* APC8). In addition, Cdc27 was found to interact with

CycA (**Figure 6A, B and Figure 6—figure supplement 1**). Remarkably, RNAi targeting

uev1a, *ben*, or *cdc27* significantly stabilized CycA proteins after the treatment with

cycloheximide (CHX), an inhibitor of protein synthesis (**Figure 6C, D and Figure 6—**

figure supplement 2). Since the K63 linkage primarily mediates lysosomal degradation

via autophagy (**Kwon and Ciechanover, 2017**), we tested CycA stabilization with a

chloroquine (CQ, a lysosome inhibitor) or MG132 (a proteasome inhibitor) treatment.

Notably, MG132, but not CQ, treatment significantly stabilized CycA proteins (**Figure**

6E). These results suggest that Uev1A, Ben, and Cdc27 cooperate to promote CycA

degradation through the proteasome rather than the lysosome.

To directly validate this, we performed ubiquitination assays for CycA in S2 cells.

Cdc27 significantly enhanced CycA ubiquitination, while this effect was markedly

reduced upon the knockdown of *uev1a*, *ben*, or both (**Figure 6F**). This result indicates

that both Uev1A and Ben are essential for APC/C-mediated proteasomal degradation of

CycA. Furthermore, we explored the roles of the seven lysine (K) residues in ubiquitin for

polyubiquitin chain formation. The 7KR (lysine to arginine) mutation completely

abolished Cdc27-promoted polyubiquitination of CycA. Intriguingly, the 6KR+K48

mutation, in which all K residues except K48 were mutated to R residues, failed to

restore polyubiquitination. In contrast, either 6KR+K11 or 6KR+K63 mutation

significantly restored polyubiquitination (**Figure 6G**). These findings suggest that the K11

and K63 linkages are primarily responsible for CycA polyubiquitination in *Drosophila*

cells. Together with previous studies (**Hofmann and Pickart, 1999; McKenna et al.,**

2001), we propose that Uev1A and Ben mediate the K63 linkage in this process.

Uev1A inhibits the overgrowth of *Drosophila* germline tumors driven by

oncogenic *Ras^{G12V}*

Given the absence of cell division in normal polyploid nurse cells (**Hammond and Laird,**

1985), their death induced by division-promoting *Ras^{G12V}* represents an artificial stress.

Notably, Uev1A was not upregulated in response to this stress (**Figure 3E**), and it

executed the function through degrading CycA (**Figure 4-6**). These findings prompted us

to investigate whether Uev1A also counteracts oncogenic *Ras*-driven tumorigenesis in

diploid cells, which undergo normal cell division. Our prior research demonstrated that

oncogenic *Ras^{G12V}* markedly promotes the overgrowth of diploid *bam*-deficient germline

tumors (**Zhang et al., 2024**), which are highly resistant to cell death (**Zhang et al., 2023;**

Zhao et al., 2018). Intriguingly, knocking down *uev1a* significantly enhanced the

overgrowth of these tumors, while overexpressing Uev1A suppressed it (**Figure 7A, B**).

These results indicate that Uev1A also plays a role in counteracting oncogenic *Ras*-
driven tumorigenesis in diploid cells.

Considering the therapeutic potential of gene upregulation in inhibiting tumor
growth, a critical concern is its impact on normal physiological processes. In this study,
we examined the impact of Uev1A overexpression on *Drosophila* oogenesis and GSC
maintenance. Notably, the *nos>Uev1A* flies remained fertile, and their ovaries appeared
morphologically similar to those of the *nos>lacZ* control flies (**Figure 7C**), indicating
normal oogenesis. Furthermore, each germarium in the ovaries of 14-day-old
nos>Uev1A flies contained a similar number of GSCs as those in the *nos>lacZ* control
flies (**Figure 7D, E**). These results suggest that Uev1A overexpression does not disrupt
normal oogenesis and GSC maintenance.

UBE2V1 and UBE2V2 inhibit the overgrowth of human colorectal tumors driven by
oncogenic *KRAS*

Our findings in *Drosophila* prompted us to explore the tumor-suppressive effects of
UBE2V1 and UBE2V2 on the growth of *RAS*-mutant human tumors. Using the Kaplan-
Meier plotter (***https://kmplot.com/analysis***), we first evaluated the correlation between
UBE2V1/2 expression and prognosis in several types of *RAS*-mutant cancer patients,
including melanoma, myeloma, lung cancer, and colorectal cancer. Among them, higher
expression levels of UBE2V1/2 were significantly associated with improved relapse-free
survival in *KRAS*-mutant colorectal cancer patients (**Figure 8A**). RNA-seq data from The
Cancer Genome Atlas (TCGA) showed that *UBE2V1* and *UBE2V2* are transcribed at
similar levels in colorectal cancer patients with oncogenic *RAS* mutations (including
KRAS, *HRAS*, and *NRAS*) as in those without such mutations (**Figure 8—figure**
supplement 1). These findings suggest that UBE2V1 and UBE2V2 are not upregulated

in response to oncogenic *RAS* mutations, paralleling the behavior of Uev1A in

Drosophila ovarian nurse cells (***Figure 3E***).

To investigate the potential tumor-suppressive roles of UBE2V1 and UBE2V2 in

KRAS-mutant colorectal cancer, we performed individual knockdowns of each gene in

two human colorectal cancer cell lines: SW480 cells (carrying the *KRAS*^{G12V} mutation)

and HCT116 cells (carrying the *KRAS*^{G13D} mutation). Notably, individual knockdown of

either *UBE2V1* or *UBE2V2* only mildly affected the proliferation of SW480 cells (***Figure***

8-figure supplement 2), suggesting potential functional redundancy between the two

proteins. However, combined knockdown of *UBE2V1* and *UBE2V2* significantly

enhanced colony formation and cell viability in both SW480 and HCT116 cells, as

demonstrated by clonogenic and CCK8 assays (***Figure 8B-G***). These results indicate

that UBE2V1 and UBE2V2 exert tumor-suppressive effects in colorectal cancer cells

harboring oncogenic *KRAS* mutations.

Next, we examined whether overexpression of UBE2V1 or UBE2V2 could

suppress the growth of SW480 and HCT116 cells. The overexpression efficiency of each

protein was confirmed by Western blotting (***Figure 9—figure supplement 1A***). Using 5-

ethynyl-2'-deoxyuridine (EdU) incorporation assays, we found that overexpression of

either UBE2V1 or UBE2V2 significantly inhibited the proliferation of both cancer cell lines

in vitro (***Figure 9—figure supplement 2A, B***). This antiproliferative effect was further

supported by clonogenic and cell viability assays (***Figure 9—figure supplement 2C-E***).

To validate the tumor-suppressive effects of UBE2V1 and UBE2V2 *in vivo*, we

established stable SW480 cell lines overexpressing each protein, with overexpression

confirmed by Western blotting (***Figure 9—figure supplement 1B***). In subcutaneous

tumorigenesis assays using *Balb/c* nude mice, overexpression of either UBE2V1 or

UBE2V2 significantly inhibited tumor formation compared to control (**_Figure 9A, B_**).

Immunohistochemical analysis of the resulting tumors showed a marked decrease in

Cyclin A expression and Ki-67-positive cells, indicating reduced proliferation (**_Figure 9C,_**

_D_). Notably, the tumor-suppressive effect of UBE2V1 was more robust than that of

UBE2V2, consistent with the stronger protective effect of UBE2V1 against _Ras^{G12V}_-

induced nurse cell death in _Drosophila_ (**_Figure 2F, G_**). Taken together, these findings

provide strong evidence for the tumor-suppressive roles of UBE2V1 and UBE2V2 in

KRAS-mutant colorectal cancer.

Discussion

It is well established that oncogenic *Ras* can induce DNA replication stress, leading to cellular senescence or death (**Hills and Diffley, 2014; Kotsantis et al., 2018**). However, our previous (**Zhang et al., 2024**) and current findings demonstrated that oncogenic Ras^{G12V} can also trigger cell death in polyploid *Drosophila* ovarian nurse cells through aberrantly promoting their division. In this study, we performed a genome-wide genetic screen and identified the E2 enzyme Uev1A as a crucial protector against this specific form of cellular stress. Mechanistically, Uev1A collaborates with the APC/C complex (E3) to facilitate the proteasomal degradation of CycA, which overexpression alone can also trigger nurse cell death. Furthermore, Uev1A and its human homologs, UBE2V1 and UBE2V2, counteract oncogenic *Ras*-driven tumorigenesis in diploid *Drosophila* germline and human colorectal tumor cells, respectively. These findings highlight the critical role of Uev1A in counteracting oncogenic *Ras* stimuli in both polyploid and diploid cells (**Figure 9E**).

Our studies reveal that the DDR pathway protects against Ras^{G12V}-induced nurse cell death (**Figure 3A, B**), suggesting that this cellular stress both activates and is subsequently suppressed by the DDR. In contrast, p53 promotes nurse cell death under the same conditions (**Figure 3A, B**). Interestingly, previous research has also demonstrated distinct roles of p53 and Lok, a crucial DDR regulator, in regulating nurse cell death during mid-oogenesis. While Lok overexpression triggers nurse cell death, p53 overexpression does not. Furthermore, Lok-induced nurse cell death remains unaffected by *p53* mutation, indicating that its mechanism operates independently of p53 (**Bakhrat et al., 2010**). The underlying mechanisms driving these differences warrant further investigation.

Of note, the suppressive effects of Uev1A on Ras^{G12V}; bam^{RNAi} germline tumors

in *Drosophila* were less pronounced than that of UBE2V1/2 on oncogenic $KRAS^{G12V}$-

driven human colorectal tumor xenografts in nude mice (**compare Figure 7A, B with**

Figure 9A, B). Our previous research has shown that Ras^{G12V}; $bam^{-/-}$ germline tumor

cells divide infrequently (**Zhang et al., 2024**). This suggests that the relatively weak

suppression observed in these tumors may be due to the fact that Uev1A's mechanism

of action is cell cycle-dependent: the more frequently tumor cells divide, the more

effectively Uev1A can suppress tumor overgrowth. We did not observe significant

negative effects of Uev1A overexpression on GSC maintenance in *Drosophila* ovaries

(**Figure 7D, E**). This is likely because GSCs also divide infrequently (**Morris and**

Spradling, 2011). Therefore, these findings underscore the importance of considering

the potential negative effects of Uev1A/UBE2V1/2 overexpression in other contexts,

particularly when cells divide rapidly.

RAS oncoproteins have long been considered "undruggable", due to the lack of

deep-binding, targetable pockets (**Moore et al., 2020**). To date, targeted therapies have

been approved only for $KRAS^{G12C}$ (**Canon et al., 2019; Ou et al., 2022; Skoulidis et al.,**

2021). Recently, small-molecule pan-KRAS degraders, developed using the proteolysis-

targeting chimeras (PROTACs) strategy, have shown promise (**Popow et al., 2024**),

though their clinical effectiveness and safety remain to be fully validated. Alternatively,

targeting key regulators in the RAS signaling pathway—such as SOS, SHP2,

Farnesyltransferase, Raf, MEK, ERK, and PI3K—has emerged as an attractive

therapeutic approach (**Moore et al., 2020**). Recent research has also explored the

strategy of hyperactivating oncogenic *RAS* to trigger cell death as a potential means to

suppress the overgrowth of human colon tumor xenografts in nude mice (**Dias et al.,**

2024). Additionally, targeting the cellular dependencies driven by oncogenic *RAS* may

trigger RAS-specific synthetic lethality, presenting a promising therapeutic approach

(**Moore et al., 2020**). Our findings highlight the tumor-suppressive effects of UBE2V1

and UBE2V2 on human colorectal tumors driven by oncogenic *KRAS* (**Figure 8 and 9**).

Notably, both of these two E2 enzymes are relatively small, with UBE2V1 consisting of

147 amino acid residues and UBE2V2 145 residues (**Figure 2E**). This raises the exciting

possibility that their upregulation, through mRNA delivery or small-molecule agonists,

could offer a promising therapeutic approach for human cancer.

Materials and Methods

Key resources table

Reagent or resource	Source	Identifier
Antibodies		
mouse anti-α-Spectrin	Developmental Studies Hybridoma Bank, DSHB	3A9
mouse anti-β-Actin	Abmart	M20011
mouse anti-β-Actin	Zenbio	200068-8F10
rabbit anti-CycA	Yuu Kimata	N/A
mouse anti-Flag	Sigma	F1804
mouse anti-Flag	Utibody	UM3009
mouse anti-γH2AV	DSHB	UNC93-5.2.1
mouse anti-HA	Utibody	UM3004
mouse anti-Myc	Utibody	UM3011
mouse anti-UBE2V2	Santa Cruz Biotechnology	sc-377254
rabbit anti-α-Tubulin	Proteintech	14555-1-AP
rabbit anti-β-Tubulin	Zenbio	380628
rabbit anti-CycA	Immunoway	YT1167
rabbit anti-Flag	Zenbio	R24091
rabbit anti-HA	Zenbio	301113
rabbit anti-Ki67	Proteintech	27309-1-AP
rabbit anti-Myc	ABclonal	AE009
rabbit anti-UBE2V1	Wanleibio	WL04482
Alexa Fluor 546 goat anti-mouse	Invitrogen	A-11030

HRP Goat anti-Mouse IgG(H+L)	SIMUBIOTECH	S2002
HRP Goat anti-Rabbit IgG(H+L)	SIMUBIOTECH	S2001

Cell lines		
Drosophila Schneider 2 (S2) cells	Duojia Pan	N/A
human 293T cells	The American Type Culture Collection, ATCC	N/A
human HCT116 cells	ATCC	N/A
human SW480 cells	ATCC	N/A

Chemicals, solutions, and kits		
BCA Protein Assay Kit	Beyotime Biotechnology	P0012
CCK8 Kit	APExBIO	K1018
Chloroquine (CQ)	Selleck	S6999
Cycloheximide (CHX)	MCE	HY-12320
DMSO	Macklin	D6258
Dulbecco's Modified Eagle Medium	Gibco	C11995500BT
EdU Incorporation Assay Kit	Beyotime Biotechnology	C0075
Fetal Bovine Serum (FBS)	Lonsera	S711-001S
Insect Culture Medium	Union	UK1000
Lipofectamine 2000	ThermoFisher	11668027
MG132	Selleck	S2619
Protein G Sepharose	Cytiva	17061801
Puromycin	Solarbio	P8230
SPARKscript II All-in-one RT SuperMix kit	SparkJade	AG0305-C
SYBR Green Premix Pro Taq HS qPCR kit	ACCURATE BIOLOGY	AG11701-S
T7 RiboMAX™ Express RNAi System	Promega	P1700

TriQuick Reagent kit	Solarbio	R1100
X-tremeGENE HP DNA Transfection Reagent	Roche	6366546001
Drosophila strains		
bam-GAL4-VP16	Erika Matunis	N/A
nos-GAL4-VP16	Ruth Lehmann	N/A
nos-cas9; FRT2A	this study	N/A
nos-cas9 (on X)	Zheng Guo	N/A
puc-lacZ	Bloomington _Drosophila_ Stock Center, BDSC	98329
UAS-bam-RNAi	BDSC	33631
UASp-BicD-RNAi	TsingHua Fly Center, THFC	THU4454
UASp-cdc27-RNAi	THFC	TH201500102.S
UASp-Cdk1	BDSC	65396
UASp-CycA	BDSC	85308
UASp-CycB	BDSC	85312
UASp-dsor1-RNAi	THFC	THU0677
UASp-fzr-RNAi	THFC	TH201500745.S
UASp-GFP	Michael Buszczak	N/A
UASp-GFP-RNAi	BDSC	44412, 44415
UASz-lacZ	Shaowei Zhao	N/A
UASp-lmgA-RNAi	THFC	THU4085
UASp-lok-RNAi	THFC	TH01867.N
UASp-mr-RNAi	THFC	THU5250
UASp-p53-RNAi	THFC	THU5318

UASp-Ras^{G12V}	Shaowei Zhao	N/A
UASp-rl-RNAi	THFC	THU3530
UASp-shtd-RNAi	THFC	TH201500835.S
UASp-Stg	BDSC	58439
UASp-tefu-RNAi	THFC	THU5591
UASp-uev1a-RNAi	BDSC	66947
UASz-flag-Ras^{G12V}	this study	N/A
UASz-UBE2V1	this study	N/A
UASz-UBE2V2	this study	N/A
UASz-uev1a	this study	N/A
UASz-Yki^{3SA}	Shaowei Zhao	N/A
y v nos-int; attP40	this study	N/A
y w nos-int; attP40	BDSC	79604
uev1a$^{\Delta1}$	this study	N/A
uev1a$^{\Delta2}$	this study	N/A
uev1a-flag	this study	N/A
All Deficiency Drosophila strains (including 7584)	The Core Facility of Drosophila Resource and Technology (CEMCS), Chinese Academy of Sciences (CAS), China	
Mouse strain		
Balb/c (CAnN.Cg-Foxn1^{nu}/Crl) nude mice	Beijing Vital River Laboratory Animal Technology Co., Ltd.	401

Plasmids		
pCDH-CMV	Addgene	72265
pCDH-CMV-UBE2V1	this study	N/A
pCDH-CMV-UBE2V2	this study	N/A
pCFD3	Addgene	49410
pCFD3-uev1a-gRNA-1	this study	N/A
pLKO.1-CMV-copGFP-PURO	GENEWIZ, Azenta Life Sciences	N/A
pLKO.1-CMV-copGFP-PURO-shNC	this study	N/A
pLKO.1-CMV-copGFP-PURO-shUBE2V1-#1	this study	N/A
pLKO.1-CMV-copGFP-PURO-shUBE2V1-#2	this study	N/A
pLKO.1-CMV-copGFP-PURO-shUBE2V2-#1	this study	N/A
pLKO.1-CMV-copGFP-PURO-shUBE2V2-#2	this study	N/A
pMD2.G	Addgene	12259
psPAX2	Addgene	12260
pU6-BbsI-chiRNA	Eric H. Baehrecke	N/A
pU6-uev1a-gRNA-2	this study	N/A
pUASt-attB	GenBank	EF362409
pUASt-APC7-Myc	this study	N/A
pUASt-Flag-ben	this study	N/A
pUASt-Flag-cycA	this study	N/A
pUASt-HA-Ub	this study	N/A
pUASt-HA-Ub^{7KR}	this study	N/A
pUASt-HA-Ub$^{6KR+K11}$	this study	N/A
pUASt-HA-Ub$^{6KR+K48}$	this study	N/A

pUASt-HA-Ub$^{6KR+K63}$	this study	N/A
pUASt-HA-uev1a	this study	N/A
pUASt-Myc-APC4	this study	N/A
pUASt-Myc-Cdc16	this study	N/A
pUASt-Myc-Cdc23	this study	N/A
pUASt-Myc-Cdc27	this study	N/A
pUASt-Myc-Fzr	this study	N/A
pUASt-Myc-Fzy	this study	N/A
pUASt-Myc-Ida	this study	N/A
pUASt-Myc-Mr	this study	N/A
pUASz1.0	*Drosophila* Genomics Resource Center, DGRC	1431
pUASz-flag-Ras^{G12V}	this study	N/A
pUASz-UBE2V1	this study	N/A
pUASz-UBE2V2	this study	N/A
pUASz-uev1a	this study	N/A
pUASz-uev1a-donor	this study	N/A
pUASz-Yki^{3SA}	this study	N/A
Software		
Adobe Photoshop 2022	San Jose, CA, USA	
ImageJ	NIH	
Prism	GraphPad Software, Inc.	
ZEN 3.0 SR imaging software	Carl Zeiss	

Data availability

The results of the deficiency screening are provided in **Source data 1**. All genotypes are

listed in **Source data 2**, and the raw quantification data can be found in **Source data 3**.

Fly husbandry

Cross experiments were conducted at 25°C, except for some performed at 29°C as

noted.

Transgenic flies

UASz-flag-Ras^{G12V}, UASz-uev1a, UASz-UBE2V1, and UASz-UBE2V2: The coding

sequences (CDSs) of *flag-Ras^{G12V}*, *uev1a-RA*, *UBE2V1*, and *UBE2V2* were cloned into

the *pUASz1.0* vector (**DeLuca and Spradling, 2018**). These plasmids were then

microinjected into fertilized fly embryos with the genotype "*y w nos-int; attP40*", resulting

in the generation of transgenic fly strains. The DNA sequence encoding 3xFlag was as

follows:

ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGAT

GACGATGACAAGCTT.

uev1a ^{Δ1} and uev1a ^{Δ2} mutants: The gRNA targeting the second coding exon of the

uev1a gene was designed with the DNA sequence "GATCCAGCTCCTCCAGTAAGCGG"

and cloned into the *pCFD3* vector (**Port et al., 2014**). The plasmids were then

microinjected into fertilized fly embryos with the genotype "*y v nos-int; attP40*" to

generate transgenic fly strain. These transgenic flies were subsequently crossed with

"*nos-cas9; FRT2A*" flies to generate *uev1a* knockout mutants, which molecular

information was identified by Sanger sequencing.

uev1a-flag knock in: The gRNA targeting the second-to-last coding exon of the *uev1a*

gene was designed with the DNA sequence "GTTATAAACCGGAGCGTTGGTGG" and

cloned into the *pU6-BbsI-chiRNA* vector. The homology arms consisted of 991 bp

upstream of the stop codon ("TAG"), followed by a 3xFlag tag sequence, the "TAG" stop

codon, and 979 bp downstream of "TAG". To prevent cleavage by the gRNA, the

targeting sequence within the upstream homology arm was mutated to

"CCTACCCTGCGCTTCATTA", ensuring that the amino acid sequence remained

unaltered. These DNA sequences were synthesized into the *pUASz1.0* vector between

the *BamHI* and *KpnI* sites and used as a double-stranded DNA (dsDNA) donor for

homologous recombination-mediated repair. The *pU6-uev1a-gRNA-2* (100 ng/μL) and

pUASz-uev1a-donor (100 ng/μL) plasmids were then co-injected into fertilized fly

embryos with the genotype "*nos-cas9 (on X)*". The resulting *uev1a-flag* knock-in fly strain

was identified by PCR and confirmed by Sanger sequencing.

Immuno-fluorescent staining

Fly ovaries were dissected in the PBS solution, fixed by the 4% paraformaldehyde

solution (diluted in PBS) for 3 hours, washed by the PBST solution (0.3% Triton X-100

diluted in PBS) for 1 hour at room temperature (RT), then incubated with the primary

antibodies (diluted in PBST) overnight at 4°C, washed by the PBST solution for 1 hour at

RT, incubated with the secondary antibodies and 0.1 μg/mL DAPI (diluted in PBST)

overnight at 4°C, washed by the PBST solution for 1 hour at RT, and subsequently

mounted using 70% glycerol (autoclaved). The primary antibodies were used at the

concentrations as follows: rabbit anti-CycA at 1:1000, mouse anti-Flag (Sigma, #F1804)

at 1:500, mouse anti-γH2AV at 1:200, and mouse anti-α-Spectrin at 1:100. The Alexa

Fluor conjugated secondary antibodies were used at 1:2,000.

Construction of plasmids used in S2 cells

The CDSs of the genes were amplified from the cDNAs derived from either S2 cells or adult wild-type (*w^{1118}*) flies and subsequently cloned into the *pUASt-attB* vector. N- or C-terminal tags were incorporated based on prior studies or structural predictions from AlphaFold. The following proteins were tagged at the N-terminus: APC4, Ben, CDC16, CDC23, Cdc27, CycA, Fzr, Fzy, Ida, Mr, Ub, Ub^{7KR}, Ub$^{6KR+K11}$, Ub$^{6KR+K48}$, Ub$^{6KR+K63}$, and Uev1A. In contrast, APC7 was tagged at the C-terminus.

Culture and transfection of S2 cells

S2 cells were cultured in insect medium with 10% FBS and incubated at 27°C without CO_2. To transfect, cells were plated in 6-well plates to reach 70% confluence and incubated for 3 hours at 27°C. Then, a pre-complexed mixture of plasmid DNA and X-tremeGENE HP DNA transfection reagent was added slowly to the cultures. The transfection process followed the manufacturer's instructions. After gentle mixing, cells were incubated at 27°C, and samples were collected 36 hours after transfection.

Immunoprecipitation (IP), immunoblotting (IB), ubiquitination and protein stability assays in S2 cells

IP assay: The transfected S2 cells were lysed using NP-40 lysis buffer supplemented with protease inhibitors at 4°C for 30 minutes. The supernatants were incubated with primary antibodies at 4°C for 3 hours, followed by incubation with Protein G Sepharose for 2 hours. The beads were washed five times with NP-40 lysis buffer and boiled for 5 minutes in 2×SDS protein loading buffer [0.25 M Tris-HCl (pH 6.8), 78 mg/mL DTT, 100 mg/mL SDS, 50% glycerol, and 5 mg/mL bromophenol blue]. Then the samples were subjected to Western blotting. The following antibodies were used: mouse anti-Flag (Utibody, #UM3009) at 1:200, mouse anti-Myc at 1:200, and mouse anti-HA at 1:200.

IB assay: After 36 hours of transfection, the S2 cells were harvested and lysed in 2×SDS protein loading buffer. The lysates were then boiled for 5 minutes and subjected to Western blotting. The following antibodies were used: mouse anti-Flag (Utibody, #UM3009) at 1:5000, rabbit anti-Flag at 1:5000, rabbit anti-Myc at 1:3000, rabbit anti-HA at 1:3000, mouse anti-β-Actin (Zenbio, #200068-8F10) at 1:5000, and rabbit anti-β-Tubulin at 1:5000.

Ubiquitination assay: S2 cells were transiently transfected with the indicated plasmid combinations. 30 hours post-transfection, cells were treated with 50 μM MG132 for 6 hours. Proteins were then immunoprecipitated and analyzed by Western blotting.

Protein stability assay: S2 cells were treated with 20 μg/mL of the protein synthesis inhibitor CHX for specified time intervals prior to harvesting.

RNAi assay in S2 cells

Two double-stranded RNAs (dsRNAs) targeting distinct regions of the relevant genes were synthesized using the T7 RiboMAX™ Express RNAi System. S2 cells were seeded in 6-well tissue culture plates and treated with 15 μg of dsRNA in the culture medium, followed by incubation for 24 hours. Expression plasmids were then transiently transfected into the cells, after which an additional 10 μg of dsRNA was added. The cells were cultured for another 36 hours before harvesting. As a negative control, dsRNA targeting the *AcGFP* gene was used. The templates for dsRNA synthesis were generated by PCR amplification from S2 cell genomic DNA using the following primers:

uev1a#1-F: GAATTAATACGACTCACTATAGGGAGAACGGAATTTCCGCTTACTG

uev1a#1-R: GAATTAATACGACTCACTATAGGGAGACGGACCGATGATCATGCC

uev1a#2-F: GAATTAATACGACTCACTATAGGGAGACACTAAAGATCGAGTGCG

uev1a#2-R: GAATTAATACGACTCACTATAGGGAGATGCCAGCTTCAGGTTCTC

ben#1-F: GAATTAATACGACTCACTATAGGGAGACCACGTCGCATCATCAAG

ben#1-R: GAATTAATACGACTCACTATAGGGAGAAGTCTTCGACGGCATATTTC

ben#2-F: GAATTAATACGACTCACTATAGGGAGACAGATCCGGACCATATTG

ben#2-R: GAATTAATACGACTCACTATAGGGAGATCAGTCTTCGACGGCATATTTC

cdc27#1-F: GAATTAATACGACTCACTATAGGGAGATCGCCCAGGATCTGATTAAC

cdc27#1-R: GAATTAATACGACTCACTATAGGGAGAGCAGCGACAGATCCTTCTTC

cdc27#2-F: GAATTAATACGACTCACTATAGGGAGAGATGATGGGCAAAAAGCTAAAG

cdc27#2-R: GAATTAATACGACTCACTATAGGGAGACCATCGGCCGATTGTTTC

AcGFP-F: GAATTAATACGACTCACTATAGGGAGATGCACCACCGGCAAGCTGCCTG

AcGFP-R: GAATTAATACGACTCACTATAGGGAGAGGCCAGCTGCACGCTGCCATC

Human cell culture

557 The human colon cancer cell lines SW480 and HCT116, as well as the human
558 embryonic kidney cell line 293T, were purchased from the American Type Culture
559 Collection (ATCC) and cultured in Dulbecco's Modified Eagle Medium supplemented
560 with 10% FBS. The cultures were maintained at 37°C with 5% CO_2 in a humidified
561 incubator.

Gene knockdown assay

Short hairpin RNA (shRNA) constructs were generated using the lentiviral vector
pLKO.1-CMV-copGFP-PURO. Lentiviral particles were produced by co-transfecting each

shRNA plasmid together with the packaging plasmids *psPAX2* and *pMD2.G* into 293T

cells using Lipofectamine 2000, following the manufacturer's protocol. SW480 and

HCT116 cells were subsequently transduced with the harvested lentiviral supernatants

to establish stable cell lines expressing *shNC* (negative control), *shUBE2V1*, or

shUBE2V2. The following shRNA sequences were used:

shNC: CCTAAGGTTAAGTCGCCCTCG

shUBE2V1 #1: CTCGGGCAGATGACATGAAAT

shUBE2V1 #2: GCATCACCACAGGCTGGCTCA

shUBE2V2 #1: GTCTTAAATCAACAACCTTCT

shUBE2V2 #2: GCTCCTCCGTCAGTTAGATTT

Overexpression assay

The lentiviral vector *pCDH-CMV* was used for gene overexpression, while *pMD2.G* and

psPAX2 served as lentiviral packaging plasmids. Target plasmids, *pCDH-CMV-UBE2V1*

and *pCDH-CMV-UBE2V2*, were synthesized by the GENEWIZ company (Suzhou,

China). Plasmids were transfected into 293T cells using Lipofectamine 2000 to generate

lentiviral particles, according to the manufacturer's protocol. SW480 and HCT116 cells

were then transduced with these lentiviruses to establish stable cell lines expressing

UBE2V1 and UBE2V2, respectively. To select for stably transduced cells, the cultures

were maintained in medium containing 2 µg/mL puromycin.

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted using the TriQuick Reagent kit and reverse-transcribed into

cDNA using the SPARKscript II All-in-one RT SuperMix kit. qRTPCR was performed

using the SYBR Green Premix Pro Taq HS qPCR kit. *GAPDH* was used as the

endogenous control for normalization. The relative mRNA levels of target genes were

determined using the $2^{-\Delta\Delta C_T}$ method. The primer sequences used were:

GAPDH-F: ACAACTTTGGTATCGTGGAAGG

GAPDH-R: GCCATCACGCCACAGTTTC

UBE2V1-F: CGGGCTCGGGAGTAAAAGTC

UBE2V1-R: AGGCCCAATTATCATCCCTGT

UBE2V2-F: TGGACAGGCATGATTATTGGGC

UBE2V2-R: CTAACACTGGTATGCTCCGGG

EdU incorporation assay

Cells were seeded in 24-well plates at a density of 100,000 cells per well. Cell

proliferation was assessed using the EdU incorporation assay kit, following the

manufacturer's instructions. Briefly, EdU reagent was added to the culture medium, and

cells were incubated for 2 hours to label DNA-synthesizing cells. After incubation, the

medium containing EdU was removed, and cells were washed with PBS, fixed with

fixative solution for 10 minutes, and then subjected to a click reaction for fluorescence

labeling. Fluorescence microscopy was used to capture images and calculate the

percentage of EdU$^+$ cells.

Colony formation assay

Cells were seeded in 6-well plates at a density of 500 cells per well and cultured at 37°C

in a 5% CO_2 incubator for 10 days without medium change. After 10 days, cells were

gently washed with PBS to remove non-adherent cells, then stained with 0.5% crystal

violet solution (containing 10% methanol and 1% acetic acid) for 15 minutes. The plates

were subsequently rinsed with water to remove excess stain and air-dried. Colonies

were photographed and counted using image analysis software.

CCK8 cell viability assay

Cells were seeded in 96-well plates at a density of 2,000 cells per well. Cell viability was

assessed over five days using a CCK8 kit following the manufacturer's instructions.

Measurements were taken on Day 0 (baseline) and daily from Day 1 to Day 4. At each

time point, 10 µL of CCK8 solution was added to each well, and the plates were

incubated for 2 hours at 37°C in a humidified incubator. Absorbance at 450 nm was

measured using a microplate reader to assess cell viability and proliferation dynamics

throughout the experimental period.

Western blotting

Cells were lysed with RIPA buffer containing protease inhibitors, and protein

concentrations were determined using a BCA Protein Assay Kit. Protein samples (20 µg

per lane) were separated by SDS-PAGE and transferred to PVDF membranes.

Membranes were blocked with 5% non-fat milk and incubated overnight at 4°C with

primary antibodies: mouse anti-β-actin (Abmart, #M20011) at 1:5,000, rabbit anti-α-

Tubulin at 1:5,000, rabbit anti-UBE2V1 at 1:2,000, and mouse anti-UBE2V2 at 1:2,000.

Following washes, membranes were incubated with HRP-conjugated secondary

antibodies and developed using ECL. Band intensities were quantified by densitometry.

Immunohistochemistry assay

Tissue sections were deparaffinized with xylene, rehydrated through a graded ethanol

series, and subjected to antigen retrieval in citrate buffer (pH 6.0) at 98°C for 10 minutes.

Endogenous peroxidase activity was blocked using 3% hydrogen peroxide, and

nonspecific binding was blocked with 5% BSA. Sections were incubated overnight at 4°C

with primary antibodies: rabbit anti-CycA at 1:200 and rabbit anti-Ki67 at 1:2,000. After

incubation with HRP-conjugated secondary antibodies, sections were developed using

DAB, counterstained with hematoxylin, and mounted. Images were captured using a

light microscope.

Animal experiment

Male *Balb/c* nude mice (7-week-old) were used to assess the tumorigenic potential of

SW480 colon cancer cells. The mice were housed under specific pathogen-free

conditions with a 12-hour light/dark cycle and had ad libitum access to food and water.

SW480 cells were stably transfected with either the empty vector *pCDH-CMV* (control),

pCDH-CMV-UBE2V1 (UBE2V1-OE), or *pCDH-CMV-UBE2V2* (UBE2V2-OE), and 5×10^6

cells were subcutaneously injected into the right flank of each mouse. Each group

consisted of six mice. Tumor growth was monitored approximately one week after

injection. Tumor volumes were measured every four days using calipers and calculated

using the formula: volume = length $\times$ width^2/2. The experiment was terminated when

tumors reached ~1,000 mm³, and mice were humanely euthanized according to

institutional and national ethical guidelines.

Image collection and processing

651 Fluorescent images were captured using a Zeiss LSM 710 confocal microscope (Carl

652 Zeiss AG, BaWü, GER) and processed with Adobe Photoshop 2022 (San Jose, CA,

653 USA), ImageJ (NIH, Bethesda, MD, USA), and ZEN 3.0 SR imaging software (Carl

654 Zeiss).

Acknowledgements

We gratefully thank Eric H. Baehrecke, Michael Buszczak, Zheng Guo, Yuu Kimata,

Ruth Lehmann, Erika Matunis, Duojia Pan, Zhaohui Wang, Wei Xiao, Addgene, ATCC,

BDSC, CEMCS, DGRC, GenBank, and THFC for providing antibodies, plasmids, cell

lines, and fly strains. This study was supported by National Natural Science Foundation

of China (NSFC) grants to Shaowei Zhao (32270841, 32070871), Shian Wu (32170714),

and Hongru Zhang (32400759), as well as by a Natural Science Foundation of Tianjin

grant (S24ZDD020) to Hongru Zhang.

Author contributions

S.Z. conceived the project. S.Z., S.W., and H.Z. supervised the studies. Q.Z., Yun.W.,

X.F., Z.W., Y.Z., L.Y., Yue.W., M.Y., D.S., and R.Z. performed the experiments. S.Z.

wrote the manuscript and all authors commented on it.

Declaration of interests

The authors declare no competing interests.

References

Andersen, P.L., Zhou, H., Pastushok, L., Moraes, T., McKenna, S., Ziola, B., Ellison,
M.J., Dixit, V.M., and Xiao, W. (2005). Distinct regulation of Ubc13 functions by the two
ubiquitin-conjugating enzyme variants Mms2 and Uev1A. J Cell Biol *170*, 745-755.
Bai, Z., Wei, M., Li, Z., and Xiao, W. (2020). Drosophila Uev1a is dually required for Ben-
dependent DNA-damage response and fly mobility. Cell Signal *74*, 109719.
Bakhrat, A., Pritchett, T., Peretz, G., McCall, K., and Abdu, U. (2010). Drosophila Chk2
and p53 proteins induce stage-specific cell death independently during oogenesis.
Apoptosis *15*, 1425-1434.
Biggs, W.H., 3rd, and Zipursky, S.L. (1992). Primary structure, expression, and signal-
dependent tyrosine phosphorylation of a Drosophila homolog of extracellular signal-
regulated kinase. Proc Natl Acad Sci U S A *89*, 6295-6299.
Broomfield, S., Chow, B.L., and Xiao, W. (1998). MMS2, encoding a ubiquitin-
conjugating-enzyme-like protein, is a member of the yeast error-free postreplication
repair pathway. Proc Natl Acad Sci U S A *95*, 5678-5683.
Canon, J., Rex, K., Saiki, A.Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T.,
Knutson, C.G., Koppada, N.*, et al.* (2019). The clinical KRAS(G12C) inhibitor AMG 510
drives anti-tumour immunity. Nature *575*, 217-223.
Chen, D., and McKearin, D.M. (2003). A discrete transcriptional silencer in the bam gene
determines asymmetric division of the Drosophila germline stem cell. Development *130*,
1159-1170.
DeLuca, S.Z., and Spradling, A.C. (2018). Efficient Expression of Genes in the
Drosophila Germline Using a UAS Promoter Free of Interference by Hsp70 piRNAs.
Genetics *209*, 381-387.
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra,
C., Garre, M., Nuciforo, P.G., Bensimon, A.*, et al.* (2006). Oncogene-induced
senescence is a DNA damage response triggered by DNA hyper-replication. Nature *444*,
638-642.
Dias, M.H., Friskes, A., Wang, S., Fernandes Neto, J.M., van Gemert, F., Mourragui, S.,
Papagianni, C., Kuiken, H.J., Mainardi, S., Alvarez-Villanueva, D.*, et al.* (2024).
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy. Cancer
Discov *14*, 1276-1301.
Dikic, I. (2017). Proteasomal and Autophagic Degradation Systems. Annu Rev Biochem
86, 193-224.
Edgar, B.A., and Lehner, C.F. (1996). Developmental control of cell cycle regulators: a
fly's perspective. Science *274*, 1646-1652.
Gaillard, H., García-Muse, T., and Aguilera, A. (2015). Replication stress and cancer.
Nat Rev Cancer *15*, 276-289.
Gimple, R.C., and Wang, X. (2019). RAS: Striking at the Core of the Oncogenic Circuitry.
Front Oncol *9*, 965.
Greil, C., Engelhardt, M., and Wäsch, R. (2022). The Role of the APC/C and Its
Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. Front Genet *13*,
941565.
Hammond, M.P., and Laird, C.D. (1985). Chromosome structure and DNA replication in
nurse and follicle cells of Drosophila melanogaster. Chromosoma *91*, 267-278.
Hills, S.A., and Diffley, J.F. (2014). DNA replication and oncogene-induced replicative
stress. Curr Biol *24*, R435-444.

Hofmann, R.M., and Pickart, C.M. (1999). Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell *96*, 645-653.

Huang, J., Wu, S., Barrera, J., Matthews, K., and Pan, D. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell *122*, 421-434.

Igarashi, T., Yano, K., Endo, S., and Shiotani, B. (2024). Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability. Cancers (Basel) *16*.

Kashevsky, H., Wallace, J.A., Reed, B.H., Lai, C., Hayashi-Hagihara, A., and Orr-Weaver, T.L. (2002). The anaphase promoting complex/cyclosome is required during development for modified cell cycles. Proc Natl Acad Sci U S A *99*, 11217-11222.

Kotsantis, P., Petermann, E., and Boulton, S.J. (2018). Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place. Cancer Discov *8*, 537-555.

Kwon, Y.T., and Ciechanover, A. (2017). The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. Trends Biochem Sci *42*, 873-886.

Lake, C.M., Holsclaw, J.K., Bellendir, S.P., Sekelsky, J., and Hawley, R.S. (2013). The development of a monoclonal antibody recognizing the Drosophila melanogaster phosphorylated histone H2A variant (γ-H2AV). G3 (Bethesda) *3*, 1539-1543.

Lilly, M.A., de Cuevas, M., and Spradling, A.C. (2000). Cyclin A associates with the fusome during germline cyst formation in the Drosophila ovary. Dev Biol *218*, 53-63.

Lilly, M.A., and Spradling, A.C. (1996). The Drosophila endocycle is controlled by Cyclin E and lacks a checkpoint ensuring S-phase completion. Genes Dev *10*, 2514-2526.

Lowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. Nature *432*, 307-315.

Ma, X., Yang, L., Yang, Y., Li, M., Li, W., and Xue, L. (2013). dUev1a modulates TNF-JNK mediated tumor progression and cell death in Drosophila. Dev Biol *380*, 211-221.

Macheret, M., and Halazonetis, T.D. (2015). DNA replication stress as a hallmark of cancer. Annu Rev Pathol *10*, 425-448.

Masrouha, N., Yang, L., Hijal, S., Larochelle, S., and Suter, B. (2003). The Drosophila chk2 gene loki is essential for embryonic DNA double-strand-break checkpoints induced in S phase or G2. Genetics *163*, 973-982.

McKenna, S., Spyracopoulos, L., Moraes, T., Pastushok, L., Ptak, C., Xiao, W., and Ellison, M.J. (2001). Noncovalent interaction between ubiquitin and the human DNA repair protein Mms2 is required for Ubc13-mediated polyubiquitination. J Biol Chem *276*, 40120-40126.

Meyer, H.J., and Rape, M. (2014). Enhanced protein degradation by branched ubiquitin chains. Cell *157*, 910-921.

Moore, A.R., Rosenberg, S.C., McCormick, F., and Malek, S. (2020). RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov *19*, 533-552.

Morris, L.X., and Spradling, A.C. (2011). Long-term live imaging provides new insight into stem cell regulation and germline-soma coordination in the Drosophila ovary. Development *138*, 2207-2215.

Muralidhar, M.G., and Thomas, J.B. (1993). The Drosophila bendless gene encodes a neural protein related to ubiquitin-conjugating enzymes. Neuron *11*, 253-266.

Nagy, O., Pál, M., Udvardy, A., Shirras, C.A., Boros, I., Shirras, A.D., and Deák, P. (2012). lemmingA encodes the Apc11 subunit of the APC/C in Drosophila melanogaster that forms a ternary complex with the E2-C type ubiquitin conjugating enzyme, Vihar and Morula/Apc2. Cell Div *7*, 9.

Neuman-Silberberg, F.S., Schejter, E., Hoffmann, F.M., and Shilo, B.Z. (1984). The Drosophila ras oncogenes: structure and nucleotide sequence. Cell *37*, 1027-1033.

Oh, C.E., McMahon, R., Benzer, S., and Tanouye, M.A. (1994). bendless, a Drosophila gene affecting neuronal connectivity, encodes a ubiquitin-conjugating enzyme homolog. J Neurosci *14*, 3166-3179.

Oh, H., and Irvine, K.D. (2009). In vivo analysis of Yorkie phosphorylation sites. Oncogene *28*, 1916-1927.

Oikemus, S.R., McGinnis, N., Queiroz-Machado, J., Tukachinsky, H., Takada, S., Sunkel, C.E., and Brodsky, M.H. (2004). Drosophila atm/telomere fusion is required for telomeric localization of HP1 and telomere position effect. Genes Dev *18*, 1850-1861.

Ou, S.I., Jänne, P.A., Leal, T.A., Rybkin, II, Sabari, J.K., Barve, M.A., Bazhenova, L., Johnson, M.L., Velastegui, K.L., Cilliers, C.*, et al.* (2022). First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1). J Clin Oncol *40*, 2530-2538.

Popow, J., Farnaby, W., Gollner, A., Kofink, C., Fischer, G., Wurm, M., Zollman, D., Wijaya, A., Mischerikow, N., Hasenoehrl, C.*, et al.* (2024). Targeting cancer with small-molecule pan-KRAS degraders. Science *385*, 1338-1347.

Port, F., Chen, H.M., Lee, T., and Bullock, S.L. (2014). Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila. Proc Natl Acad Sci U S A *111*, E2967-2976.

Rørth, P. (1998). Gal4 in the Drosophila female germline. Mech Dev *78*, 113-118.

Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C., Dimitriadoy, S., Liu, D.L., Kantheti, H.S., Saghafinia, S.*, et al.* (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell *173*, 321-337.e310.

Sancho, E., Vilá, M.R., Sánchez-Pulido, L., Lozano, J.J., Paciucci, R., Nadal, M., Fox, M., Harvey, C., Bercovich, B., Loukili, N.*, et al.* (1998). Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol Cell Biol *18*, 576-589.

Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell *88*, 593-602.

Sigrist, S.J., and Lehner, C.F. (1997). Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles. Cell *90*, 671-681.

Silva, E., Tiong, S., Pedersen, M., Homola, E., Royou, A., Fasulo, B., Siriaco, G., and Campbell, S.D. (2004). ATM is required for telomere maintenance and chromosome stability during Drosophila development. Curr Biol *14*, 1341-1347.

Skoulidis, F., Li, B.T., Dy, G.K., Price, T.J., Falchook, G.S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F.*, et al.* (2021). Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med *384*, 2371-2381.

Song, Y.H., Mirey, G., Betson, M., Haber, D.A., and Settleman, J. (2004). The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol *14*, 1354-1359.

Sudakin, V., Ganoth, D., Dahan, A., Heller, H., Hershko, J., Luca, F.C., Ruderman, J.V., and Hershko, A. (1995). The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell *6*, 185-197.

Suter, B., and Steward, R. (1991). Requirement for phosphorylation and localization of the Bicaudal-D protein in Drosophila oocyte differentiation. Cell *67*, 917-926.

Tanaka-Matakatsu, M., Thomas, B.J., and Du, W. (2007). Mutation of the Apc1 homologue shattered disrupts normal eye development by disrupting G1 cell cycle arrest and progression through mitosis. Dev Biol *309*, 222-235.

Timmons, A.K., Mondragon, A.A., Schenkel, C.E., Yalonetskaya, A., Taylor, J.D.,
Moynihan, K.E., Etchegaray, J.I., Meehan, T.L., and McCall, K. (2016). Phagocytosis
genes nonautonomously promote developmental cell death in the Drosophila ovary.
Proc Natl Acad Sci U S A *113*, E1246-1255.
Tsuda, L., Inoue, Y.H., Yoo, M.A., Mizuno, M., Hata, M., Lim, Y.M., Adachi-Yamada, T.,
Ryo, H., Masamune, Y., and Nishida, Y. (1993). A protein kinase similar to MAP kinase
activator acts downstream of the raf kinase in Drosophila. Cell *72*, 407-414.
Van Doren, M., Williamson, A.L., and Lehmann, R. (1998). Regulation of zygotic gene
expression in Drosophila primordial germ cells. Curr Biol *8*, 243-246.
Willingham, M.C., Pastan, I., Shih, T.Y., and Scolnick, E.M. (1980). Localization of the
src gene product of the Harvey strain of MSV to plasma membrane of transformed cells
by electron microscopic immunocytochemistry. Cell *19*, 1005-1014.
Xu, J., Xin, S., and Du, W. (2001). Drosophila Chk2 is required for DNA damage-
mediated cell cycle arrest and apoptosis. FEBS Lett *508*, 394-398.
Yamano, H. (2019). APC/C: current understanding and future perspectives. F1000Res *8*.
Zhang, Q., Wang, Y., Bu, Z., Zhang, Y., Zhang, Q., Li, L., Yan, L., Wang, Y., and Zhao,
S. (2024). Ras promotes germline stem cell division in Drosophila ovaries. Stem Cell
Reports *19*, 1205-1216.
Zhang, Q., Zhang, Y., Zhang, Q., Li, L., and Zhao, S. (2023). Division promotes adult
stem cells to perform active niche competition. Genetics *224*.
Zhao, S., Fortier, T.M., and Baehrecke, E.H. (2018). Autophagy Promotes Tumor-like
Stem Cell Niche Occupancy. Curr Biol *28*, 3056-3064.e3053.
Zhou, R., Silverman, N., Hong, M., Liao, D.S., Chung, Y., Chen, Z.J., and Maniatis, T.
(2005). The role of ubiquitination in Drosophila innate immunity. J Biol Chem *280*,
34048-34055.

 Figures and figure legends

Figure 1. Genetic screen identifies Uev1A as a crucial protector against *Ras^{G12V}*-

induced nurse cell death. (A) Schematic cartoon for *Drosophila* ovariole. During

oogenesis, GSC undergoes asymmetric division to generate two daughter cells: one that

self-renews and maintains GSC identity, and the other, called a cystoblast, that

differentiates to support oogenesis. As differentiation progresses, each cystoblast

performs four rounds of division with incomplete cytokinesis to produce 16

interconnected cystocytes, establishing a germline cyst. This germline cyst is then

surrounded by epithelial follicle cells to form an egg chamber. Within each egg chamber,

one of the 16 germ cells becomes the oocyte, while the remaining 15 differentiate into

nurse cells. These nurse cells undergo G/S endocycling, becoming polyploid to aid in

oocyte development. (B) Representative germarium and early-stage egg chamber with

Flag-Ras^{G12V} overexpression driven by *bam-GAL4-VP16*. The red arrow denotes an

early-stage egg chamber. (C) Genetic screening strategy. Genotype of "*bam>Ras^{G12V}*":

bam-GAL4-VP16/FM7;; UASp-Ras^{G12V}/TM6B. (D) Representative ovaries and egg

chambers (DAPI staining). The red arrows in (D) denote degrading egg chambers. Scale

bars: 200 μm. (E) Quantification data. 30 ovaries from 7-day-old flies were quantified for

each genotype. Statistical significance was determined using t test (groups = 2) or one-

way ANOVA (groups > 2): ** ($P < 0.01$) and *** ($P < 0.001$).

The online version of this article includes the following source data for figure 1:

Source data 1. Screen results.

Source data 2. All genotypes.

Source data 3. Raw quantification data.

Figure 2. Uev1A protects against the nurse cell death induced by direct overexpression of Ras^G12V. (A, C, and F) Representative samples (DAPI staining). (B) Molecular information of the *uev1a^Δ1* and *uev1a^Δ2* mutations. The red dashed lines represent nucleotide deletions. (D and G) Quantification data. 30 ovaries from 3-day-old flies were quantified for each genotype. Statistical significance was determined using t

test (groups = 2) or one-way ANOVA (groups > 2): **** (P < 0.0001). (E) Protein

sequence alignment of Uev1A, UBE2V1, and UBE2V2. It was performed using

CLUSTALW and ESPript 3.0 software.

The online version of this article includes the following source data and figure

supplement for figure 2:

Source data 2. All genotypes.

Source data 3. Raw quantification data.

Figure supplement 1. Uev1A protects against Yki^{3SA}-induced nurse cell death.

Figure 2-figure supplement 1. Uev1A protects against *Yki^3SA*-induced nurse cell

death. (A) Representative ovaries (DAPI staining). The red arrows denote degrading

egg chambers. Scale bars: 200 µm. (B) Quantification data. 30 ovaries from 7-day-old

flies were quantified for each genotype. Statistical significance was determined using t

test: * (P < 0.05) and **** (P < 0.0001). See also **Source data 2 and 3**.

Figure 3. Roles of the DDR pathway and p53 in *Ras^{G12V}*-induced nurse cell death.

(A) Representative ovaries (DAPI staining). Scale bars: 200 μm. (B) Quantification data.

30 ovaries from 3-day-old flies were quantified for each genotype. Statistical significance

was determined using one-way ANOVA: **** (P < 0.0001). (C and E) Representative

samples. Scale bars: 20 μm. (D) Schematic cartoon for *uev1a-flag* knock-in.

The online version of this article includes the following source data and figure

supplement for figure 3:

Source data 2. All genotypes.

Source data 3. Raw quantification data.

Figure supplement 1. Oncogenic *Ras^{G12V}* intrinsically triggers nurse cell death.

Figure supplement 2. Uev1A is expressed in stretch follicle cells.

Figure supplement 3. Uev1A does not directly degrade the Ras^{G12V} oncoproteins.

Figure 3-figure supplement 1. Oncogenic Ras^{G12V} intrinsically triggers nurse cell death. (A) Representative ovaries (DAPI staining). Scale bars: 200 µm. (B) Quantification data. 30 ovaries from 3-day-old flies were quantified for each genotype. Statistical significance was determined using t test: **** (P < 0.0001). See also **Source data 2 and 3**.

Figure 3-figure supplement 2. Uev1A is expressed in stretch follicle cells.

Representative ovaries.

Figure 3-figure supplement 3. Uev1A does not directly degrade the Ras^{G12V}

oncoproteins. These experiments were performed at 29°C. All images are of the same

magnification. See also **Source data 2.**

Figure 4. Uev1A collaborates with CycA to mitigate *Ras^G12V*-induced nurse cell

death. (A, C, E, and F) Representative ovaries. DAPI staining in (A and C). Scale bars:

200 μm in (A and C), 20 μm in (E and F). (B, D, and G) Quantification data. 30 ovaries

(B and D) and 15 size-matched egg chambers (G) from 3-day-old flies were quantified

for each genotype. Statistical significance was determined using t test (groups = 2) or

one-way ANOVA (groups > 2): **** ($P < 0.0001$).

The online version of this article includes the following source data for figure 4:

Source data 2. All genotypes.

Source data 3. Raw quantification data.

922
Figure 5. Uev1A collaborates with the APC/C complex to mitigate *Ras^G12V*-induced

nurse cell death. (A and C) Representative ovaries (DAPI staining). The red arrows in

(A) denote degrading egg chambers. Scale bars: 200 μm. (B and D) Quantification data.

30 ovaries from 7-day-old (B) or 3-day-old (D) flies were quantified for each genotype.

Statistical significance was determined using one-way ANOVA: **** (P < 0.0001).

The online version of this article includes the following source data and figure

supplements for figure 5:

Source data 2. All genotypes.

Source data 3. Raw quantification data.

Figure supplement 1. Expression pattern of Uev1A in germarium.

Figure supplement 2. Uev1A, Ben, and Cdc27 work together to protect nurse cells from

death during normal oogenesis.

uev1a-flag/+

936 **Figure 5-figure supplement 1. Expression pattern of Uev1A in germarium.**

937 Representative sample. See also **Source data 2.**

Figure 5-figure supplement 2. Uev1A, Ben, and Cdc27 work together to protect nurse cells from death during normal oogenesis. These experiments were performed at 29°C. (A) Representative ovaries (DAPI staining). The red arrows denote degrading egg chambers. Scale bars: 200 μm. (B) Quantification data. 30 ovaries from 7-day-old flies were quantified for each genotype. Statistical significance was determined using one-way ANOVA: **** (P < 0.0001). See also **Source data 2 and 3**.

945
Figure 6. Uev1A, Ben, and Cdc27 work together to degrade CycA through the

proteasome. (A and B) co-IP assays. The tagged proteins were co-expressed in S2

cells to assess physical interactions. As shown in (A), Uev1A interacts specifically with

three APC/C subunits: Mr (APC2), Cdc16 (APC6), and Cdc23 (APC8). Assays in (B)

demonstrate a physical interaction between CycA and Cdc27 (APC3). (C-E) CycA

stability assays. CHX: a protein-synthesis inhibitor; MG132: a proteasome inhibitor; CQ:

a lysosome inhibitor. In (D), the relative levels of CycA proteins were quantified using the

following formula: (Mean gray value of the CycA/β-Actin band at n hours post-treatment)

÷ (Mean gray value of the CycA/β-Actin band at 0 hour). Three independent replicates

were conducted at each timepoint, and statistical significance was determined using two-

way ANOVA with multiple comparisons: **** ($P < 0.0001$). (F and G) CycA ubiquitination

assays in S2 cells. As shown in (F), Cdc27 promotes CycA ubiquitination in a

Uev1A/Ben-dependent manner. Assays in (G) indicate that the K11 and K63 of ubiquitin

are required for CycA ubiquitination.

The online version of this article includes the following source data and figure

supplement for figure 6:

Source data 3. Raw quantification data.

Figure supplement 1. Co-IP results.

Figure supplement 2. RNAi efficiency assays.

Figure 6-figure supplement 1. Co-IP results. The tagged proteins were co-expressed

in S2 cells to assess physical interactions. Physical interaction was observed between

Uev1A and Ben (A). No interaction was detected between Uev1A and Cdc27, Fzr, or

Fzy (B, D, E), nor between Ben and Cdc27 (C).

Figure 6-figure supplement 2. RNAi efficiency assays. The #1 dsRNAs were

employed in RNAi assays targeting *uev1a*, *ben*, and *cdc27* in Figure 6C, D, and F.

Figure 7. Uev1A inhibits the overgrowth of germline tumors induced by oncogenic

***Ras^{G12V}*.** (A and C) Representative ovaries (DAPI staining). All images in (A) are of the

same magnification. Scar bars in (C): 200 μm. (B) Quantification data for ovarian size.

The largest 2D area of each ovary in a single confocal focal plane was scanned, and its

size was measured using ImageJ. 30 ovaries from 3-day-old flies were analyzed for

each genotype. (D) Representative samples. The GSCs within stem cell niches are

outlined by yellow dashed lines. Both images are of the same magnification. (E)

Quantification data for GSC numbers per germarium. Germ cells that directly contact

cap cells and contain dot-like spectrosomes were counted as GSCs. 100 germaria from

14-day-old flies were quantified for each genotype. In (B and E), statistical significance

was determined using t test: *n.s.* ($P > 0.05$) and * ($P < 0.05$).

The online version of this article includes the following source data for figure 7:

Source data 2. All genotypes.

Source data 3. Raw quantification data.

Figure 8. Prognostic significance and tumor-suppressive effects of UBE2V1 and UBE2V2 on *KRAS*-mutant colorectal cancer. (A) Kaplan-Meier analysis of relapse-

free survival in *KRAS*-mutant colorectal cancer patients with high or low expression

levels of UBE2V1 and UBE2V2. (B and E) The knock-down efficiency assays. The

relative mRNA levels were normalized to *GAPDH*. (C-G) Assays to evaluate the effects

of *UBE2V1-* and *UBE2V2-RNAi* on colony formation and cell viability in SW480 and

HCT116 cells. In (B, C, E, and F), three independent replicates were conducted, and

statistical significance was determined using t test. In (D and G), five (D) and six (G)

independent replicates were conducted at each time point, and statistical significance

was determined using two-way ANOVA with multiple comparisons. * ($P < 0.05$), *** ($P <$

0.001), and **** ($P < 0.0001$).

The online version of this article includes the following source data and figure

supplement for figure 8:

Source data 3. Raw quantification data.

Figure supplement 1. TCGA analysis comparing UBE2V1 and UBE2V2 expression

levels in colorectal cancer patients with and without *RAS* mutations.

Figure supplement 2. Knocking down either *UBE2V1* or *UBE2V2* alone mildly

influences the growth of colorectal cancer cell lines.

1007

1008 **Figure 8-figure supplement 1. TCGA analysis comparing UBE2V1 and UBE2V2**

1009 **expression levels in colorectal cancer patients with and without *RAS* mutations.**

1010 The TCGA patient data were downloaded from the UCSC Xena website: the RNA-seq

1011 data (Version: 05-09-2024) and the somatic mutation data (Version: 08-05-2024).

1012 Statistical significance was determined using t test: *n.s.* ($P > 0.05$).

1013

Figure 8-figure supplement 2. Knocking down either *UBE2V1* or *UBE2V2* alone

mildly influences the growth of colorectal cancer cell lines. (A and C) The knock-

down efficiency assays. The relative mRNA levels were normalized to *GAPDH*. Three

independent replicates were conducted, and statistical significance was determined

using one-way ANOVA. (B and D) Assays to evaluate the effects of *UBE2V1-* and

UBE2V2-RNAi on colony formation and cell viability in SW480 cells. Six independent

replicates were conducted at each time point, and statistical significance was determined

using two-way ANOVA with multiple comparisons. *n.s.* ($P > 0.05$), * ($P < 0.05$), ** ($P <$

0.01), *** ($P < 0.001$), and **** ($P < 0.0001$).

1023

Figure 9. Overexpression of UBE2V1 or UBE2V2 suppresses the growth of *KRAS*-mutant colorectal cancer. (A and B) Subcutaneous tumorigenesis assays in nude mice, where tumors were excised, photographed, and weighed 28 days after tumor cell injection. (C and D) Immunohistochemical staining to assess CycA expression and Ki-67 positivity in tumor tissues. All images in (C) are of the same magnification. In (B-1), six independent replicates were conducted, and statistical significance was determined

using two-way ANOVA with multiple comparisons. In (B-2 and D), six independent

replicates were conducted, and statistical significance was determined using one-way

ANOVA. ** ($P < 0.01$), *** ($P < 0.001$), and **** ($P < 0.0001$). (E) Working model. By

degrading CycA, Uev1A and the E3 APC/C complex counteract oncogenic *Ras* stimuli,

thereby protecting against cell death in polyploid *Drosophila* nurse cells and suppressing

overgrowth in diploid *Drosophila* germline and human colorectal tumor cells.

The online version of this article includes the following source data and figure

supplement for figure 9:

Source data 3. Raw quantification data.

Figure supplement 1. Validation of UBE2V1/2 overexpression in colorectal cancer cell

lines.

Figure supplement 2. UBE2V1/2 overexpression suppresses the growth of colorectal

cancer cell lines.

1043

Figure 9-figure supplement 1. Validation of UBE2V1/2 overexpression in colorectal

cancer cell lines. (A) Western blotting to confirm the transient overexpression of

UBE2V1 and UBE2V2 in SW480 and HCT116 cell lines. β-Actin was used as the loading

control. (B) Western blotting to confirm the stable overexpression of UBE2V1 and

UBE2V2 in SW480 cells, with UBE2V1-OE #1 and UBE2V2 #3 cell lines utilized in

subcutaneous tumorigenesis assays. α-Tubulin was used as the loading control. In both

(A) and (B), cells transfected with an empty overexpression vector served as the control.

Figure 9-figure supplement 2. UBE2V1/2 overexpression suppresses the growth of

colorectal cancer cell lines. (A and B) EdU incorporation assays to assess the effects

of UBE2V1 and UBE2V2 overexpression (OE) on cell proliferation in SW480 and

HCT116 cells. Empty OE vector was used as the control. All images in (A) are of the

same magnification. (C-E) Assays to evaluate the effects of UBE2V1- and UBE2V2-OE

on colony formation and cell viability in SW480 and HCT116 cells. In (B and D), three

independent replicates were conducted, and statistical significance was determined

using one-way ANOVA. In (E), five independent replicates were conducted, and

statistical significance was determined using two-way ANOVA with multiple comparisons.

* (P < 0.05), ** (P < 0.01), and **** (P < 0.0001).